Log in

NASDAQ:ABUS - Arbutus Biopharma Stock Price, Forecast & News

$2.92
-0.18 (-5.81 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$2.60
Now: $2.92
$3.10
50-Day Range
$2.59
MA: $3.06
$3.42
52-Week Range
$0.82
Now: $2.92
$4.75
Volume691,571 shs
Average Volume902,445 shs
Market Capitalization$181.36 million
P/E RatioN/A
Dividend YieldN/A
Beta2.45
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ABUS
CUSIPN/A
Phone604-419-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.90 million
Book Value$1.33 per share

Profitability

Net Income$-57,060,000.00
Net Margins-2,416.39%

Miscellaneous

Employees79
Market Cap$181.36 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.


Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Corp (NASDAQ:ABUS) released its quarterly earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.09. The biopharmaceutical company earned $1.20 million during the quarter. Arbutus Biopharma had a negative return on equity of 298.87% and a negative net margin of 2,416.39%. View Arbutus Biopharma's Earnings History.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Arbutus Biopharma.

What price target have analysts set for ABUS?

5 equities research analysts have issued 12-month target prices for Arbutus Biopharma's shares. Their forecasts range from $5.00 to $10.00. On average, they expect Arbutus Biopharma's share price to reach $7.25 in the next year. This suggests a possible upside of 148.3% from the stock's current price. View Analyst Price Targets for Arbutus Biopharma.

What is the consensus analysts' recommendation for Arbutus Biopharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arbutus Biopharma.

Has Arbutus Biopharma been receiving favorable news coverage?

News headlines about ABUS stock have been trending very negative on Saturday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arbutus Biopharma earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for Arbutus Biopharma.

Are investors shorting Arbutus Biopharma?

Arbutus Biopharma saw a decrease in short interest during the month of February. As of February 14th, there was short interest totalling 587,600 shares, a decrease of 31.5% from the January 30th total of 858,100 shares. Based on an average daily volume of 582,200 shares, the short-interest ratio is currently 1.0 days. Approximately 1.4% of the shares of the company are short sold. View Arbutus Biopharma's Current Options Chain.

Who are some of Arbutus Biopharma's key competitors?

What other stocks do shareholders of Arbutus Biopharma own?

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the folowing people:
  • Dr. Mark Joseph Murray, Pres, CEO & Director (Age 70)
  • Mr. David C. Hastings, CFO & Chief Accounting Officer (Age 58)
  • Dr. Gaston Picchio Ph.D., Chief Devel. Officer (Age 56)
  • Dr. Michael J. Sofia, Chief Scientific Officer (Age 61)
  • Dr. Elizabeth Howard, Exec. VP, Gen. Counsel & Chief Compliance Officer (Age 65)

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Jennison Associates LLC (4.74%), Point72 Asset Management L.P. (3.05%), Cowen AND Company LLC (1.49%), Bank of Montreal Can (1.15%), UBS Group AG (0.39%) and Credit Suisse AG (0.23%). View Institutional Ownership Trends for Arbutus Biopharma.

Which institutional investors are selling Arbutus Biopharma stock?

ABUS stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Bank of America Corp DE and Goldman Sachs Group Inc.. View Insider Buying and Selling for Arbutus Biopharma.

Which institutional investors are buying Arbutus Biopharma stock?

ABUS stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Point72 Asset Management L.P., Cowen AND Company LLC, Credit Suisse AG, UBS Group AG, Geode Capital Management LLC, Simplex Trading LLC and Oxford Asset Management LLP. View Insider Buying and Selling for Arbutus Biopharma.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $2.92.

How big of a company is Arbutus Biopharma?

Arbutus Biopharma has a market capitalization of $181.36 million and generates $5.90 million in revenue each year. The biopharmaceutical company earns $-57,060,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Arbutus Biopharma employs 79 workers across the globe.View Additional Information About Arbutus Biopharma.

What is Arbutus Biopharma's official website?

The official website for Arbutus Biopharma is http://www.arbutusbio.com/.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected]


MarketBeat Community Rating for Arbutus Biopharma (NASDAQ ABUS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  369 (Vote Outperform)
Underperform Votes:  286 (Vote Underperform)
Total Votes:  655
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma and other stocks. Vote "Outperform" if you believe ABUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/29/2020 by MarketBeat.com Staff

Featured Article: Why do commodities matter?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel